Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Stopped Due to Ocaliva (obeticholic acid) US labeling update, the sponsor decided to terminate the study.

Conditions

• Liver Cirrhosis, Biliary

Interventions

• DRUG: Obeticholic Acid (OCA)
• DRUG: Placebo

Sponsor

Intercept Pharmaceuticals